Pharma trade group issues guidelines for improving diversity of clinical trial participants
The pharmaceutical industry’s largest lobbying organization released guidelines on Tuesday to enhance racial and ethnic diversity among participants in clinical trials run by its member drug makers. The principles address a problem that has long hampered the development of new medicines and vaccines, including the studies of potential Covid-19 shots.
The group, the Pharmaceutical Research and Manufacturers of America, noted that the guidelines are voluntary; they do not take effect until April 2021.
